BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38545181)

  • 1. Integrated genomic and proteomic analyses identify PYGL as a novel experimental therapeutic target for clear cell renal cell carcinoma.
    Li M; Zhu G; Liu Y; Li X; Zhou Y; Li C; Wang M; Zhang J; Wang Z; Tan S; Chen W; Zhang H
    Heliyon; 2024 Mar; 10(6):e28295. PubMed ID: 38545181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated mRNA and miRNA Transcriptomic Analyses Reveals Divergent Mechanisms of Sunitinib Resistance in Clear Cell Renal Cell Carcinoma (ccRCC).
    Armesto M; Marquez M; Arestin M; Errarte P; Rubio A; Manterola L; López JI; Lawrie CH
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Cao Q; Ruan H; Yang H; Wang K; Bao L; Cheng G; Xu T; Xiao H; Wang C; Liu D; Chen K; Zhang X
    Exp Cell Res; 2018 Nov; 372(2):118-128. PubMed ID: 30267660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Wei Y; Chen X; Ren X; Wang B; Zhang Q; Bu H; Qian J; Shao P
    Front Genet; 2021; 12():680369. PubMed ID: 34306023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
    Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
    Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
    Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
    Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
    [No Abstract]   [Full Text] [Related]  

  • 8. Curcumin reverses the sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through the induction of ferroptosis via the
    Xu B; Zhu WJ; Peng YJ; Cheng SD
    Transl Cancer Res; 2021 Jul; 10(7):3158-3167. PubMed ID: 35116623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.
    Sakaguchi T; Yoshino H; Sugita S; Miyamoto K; Yonemori M; Osako Y; Meguro-Horike M; Horike SI; Nakagawa M; Enokida H
    Oncotarget; 2018 May; 9(33):23003-23017. PubMed ID: 29796168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of miR-15b Promotes Resistance to Sunitinib in Renal Cell Carcinoma.
    Lu L; Li Y; Wen H; Feng C
    J Cancer; 2019; 10(15):3389-3396. PubMed ID: 31293642
    [No Abstract]   [Full Text] [Related]  

  • 11. Expressions of miR-96-5p, miR-29b-3p, and Their Target Gene THBS1 in Clear Cell Renal Cell Carcinoma and Sunitinib Resistance.
    Wu S; Wang Y
    Altern Ther Health Med; 2023 Nov; ():. PubMed ID: 37971460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mir-144-3p Promotes Cell Proliferation, Metastasis, Sunitinib Resistance in Clear Cell Renal Cell Carcinoma by Downregulating ARID1A.
    Xiao W; Lou N; Ruan H; Bao L; Xiong Z; Yuan C; Tong J; Xu G; Zhou Y; Qu Y; Hu W; Gao Y; Ru Z; Liu L; Xiao H; Chen K; Yang H; Zhang X
    Cell Physiol Biochem; 2017; 43(6):2420-2433. PubMed ID: 29073615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
    Greene CJ; Sharma NJ; Fiorica PN; Forrester E; Smith GJ; Gross KW; Kauffman EC
    Free Radic Biol Med; 2019 Mar; 133():295-309. PubMed ID: 30553971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma.
    Ruan H; Li X; Yang H; Song Z; Tong J; Cao Q; Wang K; Xiao W; Xiao H; Chen X; Xu G; Bao L; Xiong Z; Yuan C; Liu L; Qu Y; Hu W; Gao Y; Ru Z; Chen K; Zhang X
    Exp Cell Res; 2017 Sep; 358(2):269-278. PubMed ID: 28684115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YTHDC1 is downregulated by the YY1/HDAC2 complex and controls the sensitivity of ccRCC to sunitinib by targeting the ANXA1-MAPK pathway.
    Li W; Ye K; Li X; Liu X; Peng M; Chen F; Xiong W; Wang Y; Zhu L
    J Exp Clin Cancer Res; 2022 Aug; 41(1):250. PubMed ID: 35974388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RP11-367G18.1 V2 enhances clear cell renal cell carcinoma progression via induction of epithelial-mesenchymal transition.
    Shao IH; Peng PH; Wu HH; Chen JL; Lai JC; Chang JS; Wu HT; Wu KJ; Pang ST; Hsu KW
    Cancer Med; 2023 Apr; 12(8):9788-9801. PubMed ID: 36847128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PPARα mediates sunitinib resistance via NF-κB activation in clear cell renal cell carcinoma.
    Aimudula A; Nasier H; Yang Y; Zhang R; Lu P; Hao J; Bao Y
    Int J Clin Exp Pathol; 2018; 11(5):2389-2400. PubMed ID: 31938351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Activation of HIF-1α/ACLY signaling axis promotes progression of clear cell renal cell carcinoma with VHL inactivation mutation].
    Ma Y; Wang YH; Huang S; Zou ZG; Hu L; Guo LC
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1230-1236. PubMed ID: 38058039
    [No Abstract]   [Full Text] [Related]  

  • 19. IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma.
    Jeong SU; Park JM; Yoon SY; Hwang HS; Go H; Shin DM; Ju H; Sung CO; Lee JL; Jeong G; Cho YM
    Investig Clin Urol; 2024 Jan; 65(1):84-93. PubMed ID: 38197755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial-mesenchymal transition as a mechanism of resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma.
    Hwang HS; Go H; Park JM; Yoon SY; Lee JL; Jeong SU; Cho YM
    Lab Invest; 2019 May; 99(5):659-670. PubMed ID: 30683903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.